Press Release

Propella Therapeutics Enters Merger Agreement With Astellas Pharma

November 16, 2023

Washington, DC November 16, 2023 – Cooley advised Propella Therapeutics, a privately held biopharmaceutical company that has leveraged a wholly owned proprietary platform that combines medicinal chemistry with lymphatic targeting to create new oncology drugs, on its merger agreement with Astellas Pharma in which Astellas will acquire Propella through a US subsidiary. Lawyers Aaron Binstock, Kenneth Krisko, Lindsey O’Crump and Danielle Joe led the Cooley team advising Propella.

Under the terms of the agreement, Astellas will pay approximately $175 million for all of Propella’s outstanding equity. As part of the acquisition, Astellas will acquire PRL-02, a next-generation androgen biosynthesis inhibitor being developed by Propella to treat prostate cancer. Subject to customary closing conditions, the transaction is expected to occur during Astellas’ fiscal year 2023 – which ends March 31, 2024.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has more than 1,300 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of nearly 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.